Canada Should Invest in Itself Instead of Subsidizing Foreign Biotechnology Companies

Opinion piece in Globe and Mail

Canada’s groundbreaking medical discoveries have revolutionized global health, yet foreign companies reap the rewards. This Globe and Mail opinion piece, penned by P.J. Devereaux, Maura Campbell, and David Conen, argues that it’s time to change that and builds a case for investing in Canadian biotechnology. The authors propose targeted strategies, including funding for clinical trials, tax incentives to retain biotechnology companies, and fostering collaboration between biotech firms, researchers, and investors. The time is now to invest in keeping Canadian biotechnology Canadian.